Zacks: Analysts Set $30.00 Price Target for Erytech Pharma SA (ERYP)

Share on StockTwits

Erytech Pharma SA (NASDAQ:ERYP) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Brokers have set a one year consensus price objective of $30.00 for the company and are expecting that the company will post ($0.43) EPS for the current quarter, according to Zacks. Zacks has also assigned Erytech Pharma an industry rank of 92 out of 256 based on the ratings given to related companies.

A number of research firms have recently commented on ERYP. Zacks Investment Research cut Erytech Pharma from a “buy” rating to a “sell” rating in a research report on Tuesday. ValuEngine upgraded Erytech Pharma from a “strong sell” rating to a “sell” rating in a research report on Wednesday.

Erytech Pharma stock traded down $0.45 during midday trading on Friday, reaching $7.06. The company’s stock had a trading volume of 5 shares, compared to its average volume of 2,308. Erytech Pharma has a fifty-two week low of $5.45 and a fifty-two week high of $20.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.26 and a quick ratio of 7.19. The stock has a market cap of $134.71 million, a PE ratio of 2.89 and a beta of 1.70.

Erytech Pharma Company Profile

ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.

Further Reading: How to trade on quiet period expirations

Get a free copy of the Zacks research report on Erytech Pharma (ERYP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.